10-Q: CareDx Reports Strong Q2 2026 Results, Net Income Soars

CareDx, Inc. announced robust financial results for the second quarter of 2026, with total revenue reaching $131.9 million and net income soaring to $110.6 million.

Summary

• CareDx reported a significant increase in revenue for the second quarter of 2026, reaching $131.9 million, a 52% increase year-over-year.
• Testing services revenue grew by 61% to $99.9 million, driven by a 17% increase in testing volume and higher revenue per test.
• The company achieved a net income of $110.6 million for the quarter, a substantial improvement from a net loss of $8.6 million in the prior year's second quarter.
• This strong performance was bolstered by a $113 million gain on the sale of its lab products business, which closed on June 30, 2026.
• Cash flow from operations was positive at $34.9 million for the first six months of 2026.
• The company also announced the completion of the acquisition of Naveris, Inc. for $161.8 million in cash, plus potential future milestone payments.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this filing positively due to significant revenue growth, a strong turnaround to profitability, and strategic acquisitions, despite ongoing litigation and operational expense increases.

Positives

• Total revenue increased by 52% year-over-year to $131.9 million in Q2 2026.
• Testing services revenue saw a 61% increase to $99.9 million, with a 17% rise in testing volume.
• Net income of $110.6 million in Q2 2026, a significant turnaround from a net loss in Q2 2025.
• Successful sale of the lab products business, generating a $113 million gain.
• Positive cash flow from operations of $34.9 million for the first six months of 2026.
• Acquisition of Naveris, Inc. to strengthen its position in specialty oncology and cell therapy.
• Average revenue per test increased, partly due to prior period revenue recognition.

Negatives

• Operating expenses increased across several categories, including R&D, sales & marketing, and general & administrative.
• Interest income decreased due to a lower average balance of cash and marketable securities.
• The company has a history of net losses and an accumulated deficit of $505.4 million as of June 30, 2026.

Risks

• Continued reliance on Medicare for a substantial portion of revenue, with potential for changes in reimbursement practices.
• The company faces ongoing litigation, including patent disputes with Natera.
• Potential for future impairment of goodwill and intangible assets acquired through acquisitions.
• The healthcare regulatory environment is complex and subject to change, which could impact business operations.
• Dependence on key personnel and the risk of losing key members of the senior management team.
• The company may need to raise additional capital, and there is no guarantee it will be available on favorable terms.
• Cybersecurity risks and the potential for data breaches could compromise sensitive information and expose the company to liability.

Future Outlook

The company believes its existing cash balance and expected cash from operations will be sufficient to meet its anticipated cash requirements for the next 12 months. The company may from time to time sell shares of its common stock, preferred stock, debt securities, warrants, units or rights under its shelf registration statement.

Management Comments

• The company's acquisition of Naveris is expected to strengthen its position as a precision medicine diagnostics company.
• The company is focused on empowering clinicians and improving patient outcomes through its portfolio of testing services and digital solutions.

Industry Context

StockSavvy.ai notes that CareDx's strong performance in testing services, particularly in the transplant market, aligns with the growing demand for precision medicine diagnostics. The acquisition of Naveris signals a strategic expansion into the specialty oncology and cell therapy sectors, indicating a broader market approach.

Legal Proceedings

• Ongoing litigation with Natera Inc. regarding patent infringement and false advertising claims.
• Securities class action settlement reached and approved.
• Derivative actions (Edelman and Burns) settled.
• Company previously subject to DOJ and SEC investigations, which have concluded without enforcement action against the company.

Stakeholder Impact

• Shareholders benefit from strong revenue growth and a return to profitability, potentially leading to stock price appreciation.
• Employees may benefit from the company's growth and strategic acquisitions, potentially impacting stock-based compensation.
• Clinicians and patients may benefit from the continued development and availability of advanced diagnostic solutions.

Next Steps

• Continue to expand customer base for digital solutions and pharmacy services.
• Integrate Naveris, Inc. to realize strategic and financial benefits.
• Continue to invest in research and development for new testing services and products.
• Manage ongoing litigation and potential future legal matters.

Key Dates

Recommendation

The company demonstrates strong revenue growth, a significant improvement in profitability, and strategic expansion through acquisition. While litigation and operational expenses are noted, the positive financial trajectory and market position suggest a favorable outlook for investors.

Keywords

CareDx, Form 10-Q, Quarterly Report, Testing Services, AlloSure, AlloMap, NavDx, Naveris Acquisition